Goldenwell Biotech, Inc.
GWLL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$64.35M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $64.35 Million |
|---|---|
| Enterprise Value | $64.65 Million |
| Earnings per Share | $0 |
| Beta | 4.81 |
| Outstanding Shares | 99,000,000 |
Return
| Return on Equity | 76.29% |
|---|---|
| Return on Assets | -904.85% |
| Return on Invested Capital | 357.36% |
Valuation & Multiples
| P/E Ratio | -240.74 |
|---|---|
| PEG | -39.7 |
| Price to Sales | - |
| Price to Book Ratio | -0.65 |
| Enterprise Value to Revenue | 2787.34 |
| Enterprise Value to EBIT | -254.73 |
| Enterprise Value to Net Income | -247 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.96 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Goldenwell Biotech, Inc.
3 employees
CEO: Shuang Liu
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmet...